Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
Launched by ACTELION · Sep 17, 2004
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • PAH NYHA Class II
- • Significant elevation of mean pulmonary arterial pressure
- • Significant elevation of pulmonary vascular resistance at rest
- • Limited 6-minute walk distance
- Exclusion Criteria:
- • PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt
- • Restrictive or obstructive lung disease
- • Significant vasoreactivity
- • Treatments for PAH (within 4 weeks of randomization)
About Actelion
Actelion, a biopharmaceutical company, specializes in the development and commercialization of innovative therapies for pulmonary arterial hypertension and other serious conditions. Established in 1997 and now a part of Johnson & Johnson, Actelion is committed to advancing medical science through rigorous clinical trials and research initiatives. With a focus on improving patient outcomes, the company leverages cutting-edge science and technology to deliver breakthrough treatments that address unmet medical needs, demonstrating a strong dedication to enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Cleveland, Ohio, United States
Leuven, , Belgium
Edmonton, Alberta, Canada
Torrance, California, United States
Hong Kong, , China
Madrid, , Spain
Cleveland, Ohio, United States
Toronto, Ontario, Canada
Edmonton, Alberta, Canada
Birmingham, Alabama, United States
Amsterdam, , Netherlands
Ann Arbor, Michigan, United States
Boston, Massachusetts, United States
Dallas, Texas, United States
Brisbane, , Australia
Camperdown, , Australia
Darlinghurst, , Australia
Vienna, , Austria
Calgary, Alberta, Canada
Halifax, Nova Scotia, Canada
Hamilton, Ontario, Canada
Sainte Foy, Quebec, Canada
Prague, , Czech Republic
Marseille, , France
Greifswald, , Germany
Hamburg, , Germany
Heidelberg, , Germany
Leipzig, , Germany
Regensburg, , Germany
Bologna, , Italy
Amsterdam, , Netherlands
Maastricht, , Netherlands
Barcelona, , Spain
Barcelona, , Spain
Zurich, , Switzerland
Cambridge, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials